Salvage therapy for patients with germ cell tumor

Sawsan Rashdan, Lawrence Einhorn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The introduction of cisplatin combination chemotherapy, 40 years ago, transformed metastatic testicular germ cell tumors from an almost uniformly fatal disease into a model for a curable neoplasm. Before the era of platinum combination chemotherapy, the 5-year survival rate among men with metastatic testicular germ cell tumors was 5% to 10%. Currently, the 5-year survival rate is 80% for patients with metastatic disease and 95% overall. Despite the substantial advances in the treatment of germ cell tumors, 20% to 30% of patients will relapse after first-line chemotherapy and will require additional salvage therapies. Standard-dose or high-dose chemotherapy can cure ≤ 50% of these patients. Relapses after high-dose chemotherapy generally carry a poor prognosis; however, cure is still possible in a small percentage of patients by using further salvage chemotherapy or salvage surgery.

Original languageEnglish (US)
Pages (from-to)437-443
Number of pages7
JournalJournal of Oncology Practice
Volume12
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Salvage Therapy
Germ Cell and Embryonal Neoplasms
Drug Therapy
Combination Drug Therapy
Survival Rate
Recurrence
Platinum
Cisplatin
Neoplasms
Testicular Germ Cell Tumor
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Salvage therapy for patients with germ cell tumor. / Rashdan, Sawsan; Einhorn, Lawrence.

In: Journal of Oncology Practice, Vol. 12, No. 5, 01.05.2016, p. 437-443.

Research output: Contribution to journalArticle

@article{3d2adac6858a41c0ac37b83488ebebe1,
title = "Salvage therapy for patients with germ cell tumor",
abstract = "The introduction of cisplatin combination chemotherapy, 40 years ago, transformed metastatic testicular germ cell tumors from an almost uniformly fatal disease into a model for a curable neoplasm. Before the era of platinum combination chemotherapy, the 5-year survival rate among men with metastatic testicular germ cell tumors was 5{\%} to 10{\%}. Currently, the 5-year survival rate is 80{\%} for patients with metastatic disease and 95{\%} overall. Despite the substantial advances in the treatment of germ cell tumors, 20{\%} to 30{\%} of patients will relapse after first-line chemotherapy and will require additional salvage therapies. Standard-dose or high-dose chemotherapy can cure ≤ 50{\%} of these patients. Relapses after high-dose chemotherapy generally carry a poor prognosis; however, cure is still possible in a small percentage of patients by using further salvage chemotherapy or salvage surgery.",
author = "Sawsan Rashdan and Lawrence Einhorn",
year = "2016",
month = "5",
day = "1",
doi = "10.1200/JOP.2016.011411",
language = "English (US)",
volume = "12",
pages = "437--443",
journal = "Journal of Oncology Practice",
issn = "1554-7477",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Salvage therapy for patients with germ cell tumor

AU - Rashdan, Sawsan

AU - Einhorn, Lawrence

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The introduction of cisplatin combination chemotherapy, 40 years ago, transformed metastatic testicular germ cell tumors from an almost uniformly fatal disease into a model for a curable neoplasm. Before the era of platinum combination chemotherapy, the 5-year survival rate among men with metastatic testicular germ cell tumors was 5% to 10%. Currently, the 5-year survival rate is 80% for patients with metastatic disease and 95% overall. Despite the substantial advances in the treatment of germ cell tumors, 20% to 30% of patients will relapse after first-line chemotherapy and will require additional salvage therapies. Standard-dose or high-dose chemotherapy can cure ≤ 50% of these patients. Relapses after high-dose chemotherapy generally carry a poor prognosis; however, cure is still possible in a small percentage of patients by using further salvage chemotherapy or salvage surgery.

AB - The introduction of cisplatin combination chemotherapy, 40 years ago, transformed metastatic testicular germ cell tumors from an almost uniformly fatal disease into a model for a curable neoplasm. Before the era of platinum combination chemotherapy, the 5-year survival rate among men with metastatic testicular germ cell tumors was 5% to 10%. Currently, the 5-year survival rate is 80% for patients with metastatic disease and 95% overall. Despite the substantial advances in the treatment of germ cell tumors, 20% to 30% of patients will relapse after first-line chemotherapy and will require additional salvage therapies. Standard-dose or high-dose chemotherapy can cure ≤ 50% of these patients. Relapses after high-dose chemotherapy generally carry a poor prognosis; however, cure is still possible in a small percentage of patients by using further salvage chemotherapy or salvage surgery.

UR - http://www.scopus.com/inward/record.url?scp=84969265110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969265110&partnerID=8YFLogxK

U2 - 10.1200/JOP.2016.011411

DO - 10.1200/JOP.2016.011411

M3 - Article

C2 - 27170693

AN - SCOPUS:84969265110

VL - 12

SP - 437

EP - 443

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

SN - 1554-7477

IS - 5

ER -